Trials / Terminated
TerminatedNCT02949908
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebif | Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information. |
Timeline
- Start date
- 2017-02-09
- Primary completion
- 2017-08-25
- Completion
- 2017-08-25
- First posted
- 2016-10-31
- Last updated
- 2019-01-18
- Results posted
- 2019-01-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02949908. Inclusion in this directory is not an endorsement.